PBYI Stock Recent News
PBYI LATEST HEADLINES
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present an update on Puma Biotechnology at the B. Riley Oncology Conf. on Jan. 18, 2024.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.
Puma Biotechnology is a commercial-stage biotech with a struggling approved drug, neratinib, but potential for gains. The company is focused on refining current indications for neratinib and investigating dose optimization. Puma Biotechnology's growth strategy relies on the development of alisertib, an aurora kinase A inhibitor, but success is uncertain.
Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Here, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Techne (TECH). But which of these two stocks is more attractive to value investors?
Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - CCO Conference Call Participants Ed White - H.C. Wainwright Divya Rao - Cowen Harshita Polishetty - Barclays Operator Good afternoon.
Puma Biotech (PBYI) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to loss of $0.01 per share a year ago.